Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

European Journal of Endocrinology, Vol 133, Issue 6, 718-722
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasco, A
Right arrow Articles by Frisina, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lasco, A
Right arrow Articles by Frisina, N
Articles

No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide

A Lasco, D Cucinotta, A Gigante, G Denuzzo, M Pedulla, A Trifiletti, and N Frisina

Department of Internal Medicine, University of Messina, Italy.

The aim of this study was to investigate the relationship between plasma insulin levels, peripheral insulin sensitivity and androgen secretion in ten patients with polycystic ovary syndrome and in six obese women as compared with six normal-weight control subjects. During a euglycemic-hyper-insulinemic clamp no significant change of testosterone, androstenedione or dehydroepiandrosterone sulfate plasma levels was observed in the two groups of patients or in the control subjects; insulin sensitivity was clearly reduced and was similar in polycystic ovary patients and in obese women, in spite of the different plasma androgen levels. A long-term (5 months) androgen suppression with the gonadotropin-releasing hormone agonist leuprolide was not able to improve significantly the insulin sensitivity. These results demonstrate that the short-term hyperinsulinemia achieved with the clamp technique does not affect androgen secretion and that insulin resistance, measured with the same technique, is not influenced by long-term suppression of plasma androgen levels in polycystic ovary syndrome.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
A Corbould
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women
J. Endocrinol., March 1, 2007; 192(3): 585 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Volpi, S. A. Lieberman, D. M. Ferrer, C. R. Gilkison, B. B. Rasmussen, M. Nagamani, and R. J. Urban
The Relationships Between Testosterone, Body Composition, and Insulin Resistance: A lesson from a case of extreme hyperandrogenism
Diabetes Care, February 1, 2005; 28(2): 429 - 432.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Cibula
Is insulin resistance an essential component of PCOS?: The influence of confounding factors
Hum. Reprod., April 1, 2004; 19(4): 757 - 759.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
V.L. Armstrong, M.I. Wiggam, C.N. Ennis, B. Sheridan, A.I. Traub, A.B. Atkinson, and P.M. Bell
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate
QJM, January 1, 2001; 94(1): 31 - 37.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.